Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T17:31:48.633Z.
Calculation as of: 2026-10-06T17:31:48.633Z.
Quote observation: 2026-10-06T17:30:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1f516b86ce6f8a32b007838909cf85d374f635633f340bc308fa792387434ce1
PE RATIO
N/A
Market Cap
$266.00M
PE Ratio
N/A
TTM Avg
175.46
3Y Avg
175.46
5Y Avg
175.46
Market Cap
$264.03M
PE Ratio
N/A
TTM Avg
16.07
3Y Avg
13.93
5Y Avg
35.67
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fate Therapeutics, Inc. (FATE) | $268.67M | N/A | N/A | N/A | N/A |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $268.62M | N/A | N/A | N/A | N/A |
| Scribe Therapeutics Inc. (SCTX)vs › | $267.73M | N/A | N/A | N/A | N/A |
| SAB Biotherapeutics, Inc. (SABS)vs › | $269.77M | N/A | 7.56 | 7.56 | 7.56 |
| Treace Medical Concepts, Inc. (TMCI)vs › | $270.52M | N/A | N/A | N/A | N/A |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $266.00M | N/A | 175.46 | 175.46 | 175.46 |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $262.65M | N/A | N/A | N/A | N/A |
| OraSure Technologies, Inc. (OSUR)vs › | $264.03M | N/A | 16.07 | 13.93 | 35.67 |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $262.09M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $262.00M | N/A | 15.73 | 15.73 | 15.86 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$2.31
Forward EPS (Est.)
$-1.07
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
